• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

• Solvents and Organic Chemicals Organic Compounds Nucleosides, nucleotides, and analogues Pyrimidine nucleosides Pyrimidine nucleosides
• Solvents and Organic Chemicals Organic Compounds Nucleosides, nucleotides, and analogues Pyrimidine nucleosides

Introduction to 2(1H)-Pyrimidinone, 4-amino-1-b-L-arabinofuranosyl- (CAS No. 27921-78-4)

2(1H)-Pyrimidinone, 4-amino-1-b-L-arabinofuranosyl-, also known as Ara-A or Vidarabine, is a nucleoside analog with significant antiviral properties. This compound, identified by the CAS number 27921-78-4, has been extensively studied for its therapeutic potential in treating various viral infections, particularly those caused by herpesviruses and adenoviruses. The unique structure of Ara-A, characterized by the presence of a modified pyrimidine base and an L-arabinose sugar, confers it with high specificity and efficacy against these pathogens.

The molecular formula of 2(1H)-Pyrimidinone, 4-amino-1-b-L-arabinofuranosyl- is C₁₀H₁₃N₅O₄, and its molecular weight is approximately 255.23 g/mol. The compound is a white to off-white crystalline powder that is soluble in water and slightly soluble in ethanol. Its chemical structure allows it to mimic natural nucleosides, thereby interfering with viral DNA synthesis and replication.

In clinical settings, Ara-A has been used primarily for the treatment of severe herpes simplex virus (HSV) infections, particularly in immunocompromised patients such as those with AIDS or undergoing organ transplantation. It has also shown efficacy against adenovirus infections, which can be particularly problematic in neonates and immunocompromised individuals. The mechanism of action of Ara-A involves its phosphorylation by cellular kinases to form the active triphosphate form, which then competes with natural deoxyadenosine triphosphate (dATP) for incorporation into viral DNA. Once incorporated, it causes chain termination, effectively halting viral replication.

Recent research has further elucidated the pharmacokinetics and pharmacodynamics of Ara-A. Studies have shown that the compound has a relatively short half-life in vivo, necessitating frequent dosing to maintain therapeutic levels. However, its high selectivity for viral DNA polymerases over human DNA polymerases minimizes toxicity to host cells. This selectivity is crucial for its safety profile and effectiveness as an antiviral agent.

In addition to its established use in treating viral infections, there is growing interest in exploring the broader therapeutic applications of Ara-A. For instance, preclinical studies have investigated its potential as an antitumor agent due to its ability to inhibit DNA synthesis in rapidly dividing cells. While more research is needed to fully understand its anticancer properties, preliminary findings are promising and warrant further investigation.

The development of novel delivery systems for Ara-A has also been a focus of recent research. Nanoparticle-based formulations have shown promise in enhancing the bioavailability and reducing the toxicity of the compound. These advanced delivery systems aim to optimize drug distribution and target specific tissues or cells, thereby improving treatment outcomes and patient compliance.

In conclusion, 2(1H)-Pyrimidinone, 4-amino-1-b-L-arabinofuranosyl- (CAS No. 27921-78-4) remains a valuable compound in the arsenal of antiviral therapies. Its unique chemical structure and mechanism of action make it an effective treatment option for severe viral infections. Ongoing research continues to expand our understanding of its potential applications and improve its delivery methods, ensuring that it remains a relevant and important molecule in the field of medicinal chemistry.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)